{"ticker": {"uuid": "945d0ea3-d09a-46cb-8f81-236fdbe38091", "symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "exchange": "VIE", "country": "AT", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "How FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-17T21:46:18+00:00", "published_display": "17 Jul 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin (BMRN) Wins FDA Review For VOXZOGO Full Approval In Achondroplasia", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-16T10:31:37+00:00", "published_display": "16 Jul 2026 10:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates BioMarin stock rating at Neutral", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQ1lheGxqRDBaVVA1RVB4LUFuNGpUczNSNU1EWU81RUY0Q3JEcXZOUm9XQURNVkREU1ZrUENqbDdtcjA4RWVMVFlLN0dEVjBYYk4xeVBGS2RBYzNFOXdIMENxLTJVWVB1MlBFZjBDVnpZTWQ5RzZiN2w3YXdzZkM0eXZCcEI5ZnpnQW1iRVVrZXRWcV9YdlJjX3JKQkpWcGhyazEtd2hBVGFqdUZXdGV4NkVvenNMMjBa?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T11:54:59+00:00", "published_display": "14 Jul 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZzlFZXljSDNLSjZPTklhMFRRNjg3a0RvT2VVZEJlekdQYk12dklrSE5QV3dvUkc4OG1ialNhNjNnNzJGWnY4RzRxMjJJcmxGX19EcTZ3eDV3S1JkRkJhNkludERTZGZpR1FSVnJXdXJNbndBeXQ3a0VjcG1ydmIxV293QmlYY0N5VnQxVV96bGppZVRLMGk4djNXSnJEXzhLQ28xT1RDTm1kMGc?oc=5", "source_name": "Market source", "published_at": "2026-07-13T22:16:14+00:00", "published_display": "13 Jul 2026 22:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin (BMRN) details Amicus 2025 results and $14.50-per-share merger terms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQV0Y0Nk5qWndCbHJCaTlxTVJOWkQwVUFOZmRUbFJCS3Utc1ZXMEIzZmsxUlhlNDNnZTBXMTB0d1BzS2t0ckFiLUNEZmQwbWlfN1VtTWVxeWlNZHE4WXc5NkI2RHF5NjIzR21IQy1POG9YZUtKcVlwa3F4U1l4aXJyWnVtMFNfVlkzSFhQMXZpeHlZM21HRVlGNTFTRXNEZW1RWGhySVBpdnJiTW5wYVdTMU5vMlhuWWtBX2JTNzFuY0lSdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:07:01+00:00", "published_display": "13 Jul 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPNjRHVUp0bWQ3WUdBN2Q4VGJhVU9sZWdteVJhcElTeHF2am9TZjE4WnFYZFI4RHhSSjdrTDdmckJ3TjU2WTZUMFdJSTZOdFJRVlFkdkctMXZBWkg4OVJZUkFqZ0F4WEJFNFVMODNLTTdpUVA1cGNSY0x3LTZYS0ZpYWpBYUkyY1EtTEcyNl9iUnUzYnJIdnVzaFFkbUFwbmU2MDJEUjc4ZU1kWjJxLXdKdTQ0d2xlWHIyS3hnRVhyRm43elZjUVNQQkVDQnE5S1ZoQ1B3bWlaeVpmbTVtN1E?oc=5", "source_name": "ChartMill", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQWklvMjNjZnd5RXdSRDNYSFYwVkhOTkNGTXFhalg4SVVkWGV6NS1xQmg3OWlzMlI1Q25RR0xRdnhockQ1c1FzbUNWRl9DeE9yWHpMR3haTkxjLXRwUjk0dkktc1VlYmZTSVlwdzYxaFpQRjBQLUdNbklxRnBLTVIxNWdSeXpzYml6dXVLZUJrTFU0YXNMSC1HcHRRdE1VTTQ5RTJN?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Announces New Three-Year VOXZOGO\u00ae (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxPMk9MNE9fWE52OFI2MFQ4ay1HZExONVlwM01QcUJQOW5JcXpwS1NlR0pCVE82QWpVcE45ZjZ5dHdEck9oWk9tbHplcjJQZFBuMlVRR1hWRklrNDJqUlJ0OFFfSlRXLWFoSmVVdGdTSXdkVldtNzFITkpCTjlITlcxMkJtdG5yQXJGRlBxUGtFem5RdG80cUstMmpaUjhxRW9Qb3RXTnU1a1RRRXpGWjM2NXpxT2hlYWlDVzJDdEZQN3FuRnMzeGhIekk1NmFySHV4eU9xRWtZVzdpbEVEQTlELTh1TjRhYUdMaWVLclVzWTlBR09WWEUycGpHWTNTX0hMeW1F?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxORlg3R29XNml0ZW16dzh3Q0xYSlItTU1qdDQ2X3VGUDNKTmNqUHJIQmFaQS00a0ZCNml2NFdMNHFwQTRMUWpYSnlad1puUDAySkxXZ3gwWWd3X2t3cjhYNl9LMndnVWtoWVc1c0hsSVdkUkoyTzd4TlZMbWxnTGV2a09fN2NmdXBkRTV0VFJDUGpZSFdTNUwtNlZwam5QeE84WFhWSUZWbmxOU0FrSXVz?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcjdjXzROMG1yd2x2YUZDQjZFMmtjWmtCWVFUTURkSzFiQ01JZnA1b09TeXZoOHVNeTBMSDhscThaVTBhOERZY1FoamJpQ3p6bTNiazFEVGJhdGt3dElGVWxSaDdPVjBZUVo1R2JvTXVxSWhjUVhDSEtMcHpHLVdndVlfMU1PNS1vVkF2WmJMbkM0MHowNVRzNU5sS240ckptbm52WlNR?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Q1 Revenue Beat Backed by Voxzogo Strength, Diversified Portfolio, Wedbush Says", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNUTVkU3BmbTctUHQxdHljWHZvYmEwcGp3Q3otMFl5X2lwZmFlb2FXMUY1ZlBCeER3d3pvR2JRN1NIMndNdmxwU09WSEFHRGFvcnpXeDJ1cEZRZm9MeFJ6RmsxQkxXaWJNWG1BYVhORVE3SGs2cmZ6NjJIT05wTm03U1JJd0xEZk4yOU5kY2xXV3VCMjNkdVYzcTFPYXBac0p4ajA3Z0ZrTFNxanlvRFM4VFAyeVB4anp2Y0NlZHJXWEdMS25UWjVrb3NCZ2VPM3RVWFBXeGVNWEZXcWdKSjNtbTZCLVE2dw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q1 Adjusted EPS $0.76 per Share, vs. FactSet Est of $0.91", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxOZzRfN1J2U1VKYndvb1BteHBkdEJaVTI2NU5id25VNHNrMTZ1ZkF6S3ctNHFFRXE5SEZ1dDZhZzh0QjA2dWlhU3F2dk5yNUFZN24wcVVNYnptVGtEaWxwa0ZZakhnWDhjcnQ0dG5TaHBRbGZYSWI2Y2dzcEtla2w2OUk4UkRoQy1QTEs3WldrMXhKbGhKTzNKOWlRZXJxOEY2aW13aThyenVoMWFIWUVDckw2OV9paDJYUWZFNGh0UXFHUGtDb3lxbDNZRjQ2VURYS3lJbTJRdGhUOFFsbUNYMg?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports First Quarter 2026 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaE9PQVp2VzJjOWkza2VZZ25vUGRjY2UzVVkxNTFLeF9GTW1NUURkeXdNZmxIMURicnZZdklFYWtzdWJZQlotSkZMNE95YkdxY2NRb29NcGU2d0dwZ0MzWWhicEFiNnRDZldxZEZNdHdWSWxhQkR2N2dNd19VbzA0VTZTcDB1RGhBU0FESDRjRTdDRWhYQXpSUWJHQUtUVFZkLUpXeVJjbTRIZHBUODNhMFM1YWdqNDVremtWblNManY?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Completes Acquisition of Amicus Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdVlTT1VIM19nY2JWQVN0b1hZSEpRSHRlOWVTaUVkQ2pBeVpwSnZWZnlwcVIwR3VWTkFza2ZSUDF1ZW42NE9zRmk0MUtDWU1iM1RPWlBoanhLQ3RLUmJOeHhwN3ZxYjdQSTFjR3QzRWU2WHktdU85VkRYWmZtUmVheWdJYkItUGdZZTJOcDl0dERETXhsWlZQbThjaWxNVF9CdTZBbk94RDVlTlJ6bVE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNdFZ6TTl1TXh6Yk5hakNaUEpMS3lyVHdJR25hTVdPREdsSFQ5c1VldEpxTUp3bmc3dXBtU00teFVxdVpjS1QyXzJJNXFtZFgwMUlMRU1nblVzbkpnM0RGRGJuM1VTUHYwTHlyY01LZDRRSHRKNms5TzRQOURkcFB1d2F4b0FGSktxYlZWUEFDU1hIY1FqZlMzVVlMLVFteVdtSjlveGFQcjkyU0RQbEx2Vkd2clBKWmJmcFFYdlFiZFc2NW0tRllOcEtlTW5zbFZyZF9Cbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc.: Target Price Consensus and Analysts Recommendations | BMRN | US09061G1013", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOYWxmVGctVVB3NW1KdUJOaDhfaktvaF81Z2kzZ1FnSlF1c1Q0Uy1xeE9weUQzdS0wQmwzNGtxY21yLXdSQ094THpObGdOQ2tiSEY4WEZiY2hETlJsd21lby1KV3EtMVZWcGx5MS1JMVBkSkp6SGNOSFJBeHV3aGxEODhPNE5jWGEzU2tnSg?oc=5", "source_name": "marketscreener.com", "published_at": "2020-08-18T18:15:29+00:00", "published_display": "18 Aug 2020 18:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "How FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-17T21:46:18+00:00", "published_display": "17 Jul 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin (BMRN) Wins FDA Review For VOXZOGO Full Approval In Achondroplasia", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQTk1jWWFSNFlQVTctVU1fRzUwOFdETGc5OGlRQ18xZ09DR2VLZm51Rjc0SWQwTEFFY1pDV3h2RmhqVDJBNElMZzlWbG5IZ19yZGI0R0UwNUx4V1liaElPcUlqdjlyZ3lndi1xVUJSSVlzLWgwb0gyRHIzMzk1blFRcWd0cGlXaHAyaWpzTjF1MmFORUJNNlg4YjV0SzhLenlCMm1jbjdFU0JEQ1lmaFFtN0pMZlJWS0tBczEzQ0JPODhJc1NTbHF6RmRhVm40YjIzMU5XaTdZa1FZTTk0MWJvcUJUZ3VpN1VOY2pBTUxB0gHzAUFVX3lxTE9XelRZelJuUXlCcGpkeU1uWlpNNFh6RFZFNjJWRnk1Zng2THR4anlkMHJ6cnRma25RVGRYSXowdDBHVXBjaTBzQTR2eW1tQjRwWWR3a09DYzdfNHN5MXpjcUNPdF9TUmJKVEpPTTEtM2FaVkFZRDY3aFV5d2N5T2ZoV0p6T0hBd1NxY3AxQ0x3TURQd05tQ1ZTRmdtSlp6cmdWRUdYazFzbHNzS2gwOEhScnlJbEZCYTRMV1BPTGd5RlpGUjBydGhCSjdGQlZucUxXaHFUMVYyTkdDZVB1NTBDSmNzUUlfcm9GVkxITjY4Mkt4QQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-16T10:31:37+00:00", "published_display": "16 Jul 2026 10:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates BioMarin stock rating at Neutral", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQ1lheGxqRDBaVVA1RVB4LUFuNGpUczNSNU1EWU81RUY0Q3JEcXZOUm9XQURNVkREU1ZrUENqbDdtcjA4RWVMVFlLN0dEVjBYYk4xeVBGS2RBYzNFOXdIMENxLTJVWVB1MlBFZjBDVnpZTWQ5RzZiN2w3YXdzZkM0eXZCcEI5ZnpnQW1iRVVrZXRWcV9YdlJjX3JKQkpWcGhyazEtd2hBVGFqdUZXdGV4NkVvenNMMjBa?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T11:54:59+00:00", "published_display": "14 Jul 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZzlFZXljSDNLSjZPTklhMFRRNjg3a0RvT2VVZEJlekdQYk12dklrSE5QV3dvUkc4OG1ialNhNjNnNzJGWnY4RzRxMjJJcmxGX19EcTZ3eDV3S1JkRkJhNkludERTZGZpR1FSVnJXdXJNbndBeXQ3a0VjcG1ydmIxV293QmlYY0N5VnQxVV96bGppZVRLMGk4djNXSnJEXzhLQ28xT1RDTm1kMGc?oc=5", "source_name": "Market source", "published_at": "2026-07-13T22:16:14+00:00", "published_display": "13 Jul 2026 22:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin (BMRN) details Amicus 2025 results and $14.50-per-share merger terms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQV0Y0Nk5qWndCbHJCaTlxTVJOWkQwVUFOZmRUbFJCS3Utc1ZXMEIzZmsxUlhlNDNnZTBXMTB0d1BzS2t0ckFiLUNEZmQwbWlfN1VtTWVxeWlNZHE4WXc5NkI2RHF5NjIzR21IQy1POG9YZUtKcVlwa3F4U1l4aXJyWnVtMFNfVlkzSFhQMXZpeHlZM21HRVlGNTFTRXNEZW1RWGhySVBpdnJiTW5wYVdTMU5vMlhuWWtBX2JTNzFuY0lSdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:07:01+00:00", "published_display": "13 Jul 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPNjRHVUp0bWQ3WUdBN2Q4VGJhVU9sZWdteVJhcElTeHF2am9TZjE4WnFYZFI4RHhSSjdrTDdmckJ3TjU2WTZUMFdJSTZOdFJRVlFkdkctMXZBWkg4OVJZUkFqZ0F4WEJFNFVMODNLTTdpUVA1cGNSY0x3LTZYS0ZpYWpBYUkyY1EtTEcyNl9iUnUzYnJIdnVzaFFkbUFwbmU2MDJEUjc4ZU1kWjJxLXdKdTQ0d2xlWHIyS3hnRVhyRm43elZjUVNQQkVDQnE5S1ZoQ1B3bWlaeVpmbTVtN1E?oc=5", "source_name": "ChartMill", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQWklvMjNjZnd5RXdSRDNYSFYwVkhOTkNGTXFhalg4SVVkWGV6NS1xQmg3OWlzMlI1Q25RR0xRdnhockQ1c1FzbUNWRl9DeE9yWHpMR3haTkxjLXRwUjk0dkktc1VlYmZTSVlwdzYxaFpQRjBQLUdNbklxRnBLTVIxNWdSeXpzYml6dXVLZUJrTFU0YXNMSC1HcHRRdE1VTTQ5RTJN?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Announces New Three-Year VOXZOGO\u00ae (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxPMk9MNE9fWE52OFI2MFQ4ay1HZExONVlwM01QcUJQOW5JcXpwS1NlR0pCVE82QWpVcE45ZjZ5dHdEck9oWk9tbHplcjJQZFBuMlVRR1hWRklrNDJqUlJ0OFFfSlRXLWFoSmVVdGdTSXdkVldtNzFITkpCTjlITlcxMkJtdG5yQXJGRlBxUGtFem5RdG80cUstMmpaUjhxRW9Qb3RXTnU1a1RRRXpGWjM2NXpxT2hlYWlDVzJDdEZQN3FuRnMzeGhIekk1NmFySHV4eU9xRWtZVzdpbEVEQTlELTh1TjRhYUdMaWVLclVzWTlBR09WWEUycGpHWTNTX0hMeW1F?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxORlg3R29XNml0ZW16dzh3Q0xYSlItTU1qdDQ2X3VGUDNKTmNqUHJIQmFaQS00a0ZCNml2NFdMNHFwQTRMUWpYSnlad1puUDAySkxXZ3gwWWd3X2t3cjhYNl9LMndnVWtoWVc1c0hsSVdkUkoyTzd4TlZMbWxnTGV2a09fN2NmdXBkRTV0VFJDUGpZSFdTNUwtNlZwam5QeE84WFhWSUZWbmxOU0FrSXVz?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcjdjXzROMG1yd2x2YUZDQjZFMmtjWmtCWVFUTURkSzFiQ01JZnA1b09TeXZoOHVNeTBMSDhscThaVTBhOERZY1FoamJpQ3p6bTNiazFEVGJhdGt3dElGVWxSaDdPVjBZUVo1R2JvTXVxSWhjUVhDSEtMcHpHLVdndVlfMU1PNS1vVkF2WmJMbkM0MHowNVRzNU5sS240ckptbm52WlNR?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Q1 Revenue Beat Backed by Voxzogo Strength, Diversified Portfolio, Wedbush Says", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNUTVkU3BmbTctUHQxdHljWHZvYmEwcGp3Q3otMFl5X2lwZmFlb2FXMUY1ZlBCeER3d3pvR2JRN1NIMndNdmxwU09WSEFHRGFvcnpXeDJ1cEZRZm9MeFJ6RmsxQkxXaWJNWG1BYVhORVE3SGs2cmZ6NjJIT05wTm03U1JJd0xEZk4yOU5kY2xXV3VCMjNkdVYzcTFPYXBac0p4ajA3Z0ZrTFNxanlvRFM4VFAyeVB4anp2Y0NlZHJXWEdMS25UWjVrb3NCZ2VPM3RVWFBXeGVNWEZXcWdKSjNtbTZCLVE2dw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q1 Adjusted EPS $0.76 per Share, vs. FactSet Est of $0.91", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxOZzRfN1J2U1VKYndvb1BteHBkdEJaVTI2NU5id25VNHNrMTZ1ZkF6S3ctNHFFRXE5SEZ1dDZhZzh0QjA2dWlhU3F2dk5yNUFZN24wcVVNYnptVGtEaWxwa0ZZakhnWDhjcnQ0dG5TaHBRbGZYSWI2Y2dzcEtla2w2OUk4UkRoQy1QTEs3WldrMXhKbGhKTzNKOWlRZXJxOEY2aW13aThyenVoMWFIWUVDckw2OV9paDJYUWZFNGh0UXFHUGtDb3lxbDNZRjQ2VURYS3lJbTJRdGhUOFFsbUNYMg?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports First Quarter 2026 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaE9PQVp2VzJjOWkza2VZZ25vUGRjY2UzVVkxNTFLeF9GTW1NUURkeXdNZmxIMURicnZZdklFYWtzdWJZQlotSkZMNE95YkdxY2NRb29NcGU2d0dwZ0MzWWhicEFiNnRDZldxZEZNdHdWSWxhQkR2N2dNd19VbzA0VTZTcDB1RGhBU0FESDRjRTdDRWhYQXpSUWJHQUtUVFZkLUpXeVJjbTRIZHBUODNhMFM1YWdqNDVremtWblNManY?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Completes Acquisition of Amicus Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdVlTT1VIM19nY2JWQVN0b1hZSEpRSHRlOWVTaUVkQ2pBeVpwSnZWZnlwcVIwR3VWTkFza2ZSUDF1ZW42NE9zRmk0MUtDWU1iM1RPWlBoanhLQ3RLUmJOeHhwN3ZxYjdQSTFjR3QzRWU2WHktdU85VkRYWmZtUmVheWdJYkItUGdZZTJOcDl0dERETXhsWlZQbThjaWxNVF9CdTZBbk94RDVlTlJ6bVE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNdFZ6TTl1TXh6Yk5hakNaUEpMS3lyVHdJR25hTVdPREdsSFQ5c1VldEpxTUp3bmc3dXBtU00teFVxdVpjS1QyXzJJNXFtZFgwMUlMRU1nblVzbkpnM0RGRGJuM1VTUHYwTHlyY01LZDRRSHRKNms5TzRQOURkcFB1d2F4b0FGSktxYlZWUEFDU1hIY1FqZlMzVVlMLVFteVdtSjlveGFQcjkyU0RQbEx2Vkd2clBKWmJmcFFYdlFiZFc2NW0tRllOcEtlTW5zbFZyZF9Cbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc.: Target Price Consensus and Analysts Recommendations | BMRN | US09061G1013", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOYWxmVGctVVB3NW1KdUJOaDhfaktvaF81Z2kzZ1FnSlF1c1Q0Uy1xeE9weUQzdS0wQmwzNGtxY21yLXdSQ094THpObGdOQ2tiSEY4WEZiY2hETlJsd21lby1KV3EtMVZWcGx5MS1JMVBkSkp6SGNOSFJBeHV3aGxEODhPNE5jWGEzU2tnSg?oc=5", "source_name": "marketscreener.com", "published_at": "2020-08-18T18:15:29+00:00", "published_display": "18 Aug 2020 18:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 73, "total_relevant": 16, "sentiment_summary": {"positive": 3, "negative": 0, "neutral": 13, "score": 52, "total": 16, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 71, "events": [{"event": "general", "label": "Market update", "weight": 2.75, "count": 5}, {"event": "earnings", "label": "Earnings", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 3, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 51.72, "latest_week": "2026-07-10", "one_week_move": -0.8, "four_week_move": 6.8, "twelve_week_move": 11.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.918231, "market_dynamics_buy_signal": false, "relative_strength": -13.311939, "fair_value_gap": -19.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 44.2819, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.8% over one week, +6.8% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 47, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 4}, {"label": "PR Newswire", "count": 4}, {"label": "marketscreener.com", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "Investing.com", "count": 1}, {"label": "Stock Titan", "count": 1}, {"label": "ChartMill", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 16}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 5}, {"label": "Earnings", "count": 5}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "71/100 classification confidence."}, {"label": "Company focus", "value": "16", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.8% over one week, +6.8% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "How FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Story"}], "updated_at": "2026-07-18T08:14:08.837622+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}